ALGERNON PHARMACEUT. A
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. It pipeline includes Ifenprodil, which is in Phase 2b clinical trial for the treatment of idiopathic pulmonary fibrosi… Read more
Market Cap & Net Worth: ALGERNON PHARMACEUT. A (AGW0)
ALGERNON PHARMACEUT. A (F:AGW0) has a market capitalization of $650.52K (€633.74K) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #37217 globally and #4747 in its home market, demonstrating a -43.94% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ALGERNON PHARMACEUT. A's stock price €0.02 by its total outstanding shares 34256179 (34.26 Million).
ALGERNON PHARMACEUT. A Market Cap History: 2016 to 2025
ALGERNON PHARMACEUT. A's market capitalization history from 2016 to 2025. Data shows change from $226.80 Million to $650.52K (-49.74% CAGR).
ALGERNON PHARMACEUT. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ALGERNON PHARMACEUT. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of AGW0 by Market Capitalization
Companies near ALGERNON PHARMACEUT. A in the global market cap rankings as of March 19, 2026.
Key companies related to ALGERNON PHARMACEUT. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ALGERNON PHARMACEUT. A Historical Marketcap From 2016 to 2025
Between 2016 and today, ALGERNON PHARMACEUT. A's market cap moved from $226.80 Million to $ 650.52K, with a yearly change of -49.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €650.52K | -7.50% |
| 2024 | €703.26K | -35.48% |
| 2023 | €1.09 Million | -92.00% |
| 2022 | €13.63 Million | -45.04% |
| 2021 | €24.79 Million | -78.80% |
| 2020 | €116.92 Million | +421.57% |
| 2019 | €22.42 Million | -61.94% |
| 2018 | €58.90 Million | -81.18% |
| 2017 | €312.95 Million | +37.98% |
| 2016 | €226.80 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of ALGERNON PHARMACEUT. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $650.52K USD |
| MoneyControl | $650.52K USD |
| MarketWatch | $650.52K USD |
| marketcap.company | $650.52K USD |
| Reuters | $650.52K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.